Lynne Murray has over 20 years of experience in drug discovery and development ranging from start-up biotech settings to large pharma. She is now VP Research and Head of UK Research Organisation and Site Head for Oxford, UK for Gilead Sciences. Lynne was Chief Scientific Officer for MiroBio when it was acquired by Gilead Sciences. Prior to joining MiroBio she served as Head of Regeneration at AstraZeneca’s early respiratory & immunology department. Over her tenure, she led multiple large and small molecule programs and gained significant business development experience in the partnering & strategy department at AZ.
Before this, she was Director of Pharmacology at a U.S.-based biotech, Promedior and also held a research position at Janssen, Philadelphia after her postdoc at UCLA. Dr. Murray received her MBA from University of Cambridge Judge Business School and holds a Ph.D. in immunology and pathology from Imperial College London.